MedTrace Logo

Olmesartan Comparison to Losartan in Hypertensive Subjects

NCT00949884 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 941

Last updated 2011-03-09

Study results available
· View outcomes & findings →

Summary

This study will evaluate the efficacy and safety of the FDA approved blood pressure medication olmesartan medoxomil compared to the FDA approved medication losartan potassium.

Conditions

Interventions

DRUG

olmesartan medoxomil

Oral tablets, once daily, at either 20mg or 40mg daily.

DRUG

Placebo

placebo oral tablets once daily for two weeks

DRUG

losartan potassium

losartan potassium oral tablet at either 50mg or 100 mg daily dose.

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-08-31
Primary Completion
2010-01-31
Completion
2010-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00949884 on ClinicalTrials.gov